Overall and progression-free survival in patients with primary lung adenocarcinoma expressing two or more biomarkers: a systematic review of the literature

Vista sencilla de ítem
dc.contributor.advisorArias Ortiz, Wanderley Augusto
dc.contributor.authorSilva Aparicio, Adriana Maritza
dc.contributor.authorParada Gereda, Henry Mauricio
dc.contributor.authorParra Medina, Rafael Santiago
dc.contributor.authorArias Ortiz, Wanderley Augusto
dc.contributor.orcidParra Medina, Rafael Santiago [0000-0002-8428-5837]
dc.contributor.orcidArias Ortiz, Wanderley Augusto [0000-0002-6606-4627]
dc.date.accessioned2023-02-10T20:23:35Z
dc.date.available2023-02-10T20:23:35Z
dc.date.issued2023
dc.description.abstractIntroduction: Lung cancer is one of the most prevalent types of malignancy and a leading cause of cancer-related death. Substantial improvements in the understanding of disease biology, the refinement of therapeutic approaches, and the implementation of predictive biomarkers for treatment selection have resulted in remarkable advancements and transformed cancer outcomes for many patients. Given the numerous targeted therapies available against cancer, molecular characterization of tumour biomarkers has become essential for selecting the therapeutic options that offer the best survival outcomes. So far, most studies have evaluated therapeutic outcomes in relation to a single tumour biomarker. In contrast, data on patients with tumours expressing two or more biomarkers are limited. Therefore, this systematic literature review aimed to describe the therapeutic outcome, in terms of survival, in patients with primary lung adenocarcinoma harbouring two or more biomarkers compared to patients with tumours positive for a single biomarker. Methods: A search for cross-sectional observational studies on lung cancer published between January 2017 and December 2021 was conducted in the PubMed, Embase, Cochrane, Lilacs, and Google academic databases. Articles reporting dual biomarker expression were selected according to the Preferred Reporting Items for Systematic Reviews (PRISMA) guideline. Results: Fourteen cross-sectional observational studies were included in the systematic review. Three studies reported survival data in patients with lung cancer positive for a mutated EGFR (epidermal growth factor) and overexpressing PD-L1 (programmed death ligand 1); two studies dealt with cases expressing ALK (anaplastic lymphoma kinase) rearrangements and overexpressing PD-L1; and nine studies concerned patients with concurrent EGFR, ALK, and ROS1 (proto-oncogene 1 ROS1) alterations. On average, progression-free survival was 8.78 months in patients carrying tumours with concomitant biomarker expression and 12.13 months in those with a single biomarker. In addition, overall survival data were 26.07 months and 25.65 months for patients with tumours with dual or single biomarker expression, respectively. Conclusions: Progression-free survival and overall survival were shorter in patients with lung cancer with dual biomarker expression than in cases positive for a single biomarker.spa
dc.description.abstractenglishIntroduction: Lung cancer is one of the most prevalent types of malignancy and a leading cause of cancer-related death. Substantial improvements in the understanding of disease biology, the refinement of therapeutic approaches, and the implementation of predictive biomarkers for treatment selection have resulted in remarkable advancements and transformed cancer outcomes for many patients. Given the numerous targeted therapies available against cancer, molecular characterization of tumour biomarkers has become essential for selecting the therapeutic options that offer the best survival outcomes. So far, most studies have evaluated therapeutic outcomes in relation to a single tumour biomarker. In contrast, data on patients with tumours expressing two or more biomarkers are limited. Therefore, this systematic literature review aimed to describe the therapeutic outcome, in terms of survival, in patients with primary lung adenocarcinoma harbouring two or more biomarkers compared to patients with tumours positive for a single biomarker. Methods: A search for cross-sectional observational studies on lung cancer published between January 2017 and December 2021 was conducted in the PubMed, Embase, Cochrane, Lilacs, and Google academic databases. Articles reporting dual biomarker expression were selected according to the Preferred Reporting Items for Systematic Reviews (PRISMA) guideline. Results: Fourteen cross-sectional observational studies were included in the systematic review. Three studies reported survival data in patients with lung cancer positive for a mutated EGFR (epidermal growth factor) and overexpressing PD-L1 (programmed death ligand 1); two studies dealt with cases expressing ALK (anaplastic lymphoma kinase) rearrangements and overexpressing PD-L1; and nine studies concerned patients with concurrent EGFR, ALK, and ROS1 (proto-oncogene 1 ROS1) alterations. On average, progression-free survival was 8.78 months in patients carrying tumours with concomitant biomarker expression and 12.13 months in those with a single biomarker. In addition, overall survival data were 26.07 months and 25.65 months for patients with tumours with dual or single biomarker expression, respectively. Conclusions: Progression-free survival and overall survival were shorter in patients with lung cancer with dual biomarker expression than in cases positive for a single biomarker.eng
dc.description.degreelevelMaestríaspa
dc.description.degreenameMagíster en Epidemiologíaspa
dc.format.mimetypeapplication/pdf
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/9940
dc.language.isoeng
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.grantorUniversidad El Bosquespa
dc.publisher.programMaestría en Epidemiologíaspa
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccess
dc.rights.accessrightshttps://purl.org/coar/access_right/c_14cb
dc.rights.localAcceso cerradospa
dc.subjectReceptor del factor de crecimiento epidérmico (EGFR)spa
dc.subjectLinfoma anaplásico quinasa (ALK)spa
dc.subjectLigando de muerte programada 1 (PD-L1)spa
dc.subjectAdenocarcinoma de pulmónspa
dc.subject.keywordsEpidermal growth factor receptor (EGFR)spa
dc.subject.keywordsAnaplastic lymphoma kinase (ALK)spa
dc.subject.keywordsProgrammed death-ligand 1 (PD-L1)spa
dc.subject.keywordsLung adenocarcinomaspa
dc.subject.nlmWA 105
dc.titleOverall and progression-free survival in patients with primary lung adenocarcinoma expressing two or more biomarkers: a systematic review of the literaturespa
dc.title.translatedOverall and progression-free survival in patients with primary lung adenocarcinoma expressing two or more biomarkers: a systematic review of the literaturespa
dc.type.coarhttps://purl.org/coar/resource_type/c_bdcc
dc.type.coarversionhttps://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesis/Trabajo de grado - Monografía - Maestríaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Overall and progression-free survival in patients with primary lung adenocarcinoma expressing two or more biomarkers: a systematic review of the literature
Tamaño:
166.21 KB
Formato:
Adobe Portable Document Format
Descripción:
Overall and progression-free survival in patients with primary lung adenocarcinoma expressing two or more biomarkers: a systematic review of the literature
Descargar
Bloque de licencias
Mostrando 1 - 2 de 2
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.95 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
No hay miniatura disponible
Nombre:
CARTA REPOSITORIO.pdf
Tamaño:
372.68 KB
Formato:
Adobe Portable Document Format
Descripción:
Carta de autorización
Descargar

Colecciones

Maestría en Epidemiología